Teva
Manufacturing · Israel · 10K+ Employees
View Company Info for Free
Overview
Headquarters
124 Dvora Hanevi'a St, Tel Aviv, Tel Avi...Phone Number
+972 39148213Website
www.tevapharm.comRevenue
$17.3 BillionStock Symbol
TEVAIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
2
2
2
2
1
About Teva
Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical leader focused on improving health outcomes for patients worldwide. Enabled by a world-class generics business, Teva develops, manufactures, and delivers a broad portfolio of medicines, including complex generics, biosimilars, innovative therapies, and pharmacy brands. The company is dedicated to addressing unmet patient needs by advancing scientific research, expanding access to quality medicines, and streamlining the delivery of treatments -from established generics to cutting-edge therapeutic solutions.Explore more
Teva Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Teva your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Teva
Earning: See what the market has to say on Teva recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Teva launches new products
Click to see if Teva had a recent Job posting/layoffs
Check out if Teva is spiking on competitors!
Check if Teva has recently received funding, and reach out quickly before it becomes old news!
Teva, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Teva has new funding data
Recommended Actions
Find VP level buyers at Teva
Find 2 more new buyers
Compare Similar Companies to Teva
Compare insights from companies similar to Teva, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Teva
$17.3B
10K+
Public
$99.3B
1901
BS
Brian SavageExecutive Vice President & Interim Chief Legal Officer
$72.2B
10K+
Public
-
1876
KD
Kevin DuffinVice President, Chief Operating Officer, and Head of Core Technologies
$3.1B
10K+
Public
-
1935
Ashish VigCEO, Cipla Digital Health & Leader (eCommerce, Modern Trade, Organized Retail Pharmacies)
Company Profile Activity
Activity Insights
Teva is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Teva is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Teva.
Teva financials insights
Gather financial insights about Teva, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Multiple Rounds
$11.3B
2012
Multiple Rounds
$7.6B
2015
Debt
$2.4B
Debt
$33.8B
2016
Multiple Rounds
$28.1B
2018
Corporate Investment
$358M
Debt
$4.5B
2019
Debt
$2.3B
2026
Private Equity
$400M
Teva Tech Stack
A closer look at the technologies used by Teva
See more technologies
Most Recent Scoops
Earnings
reported net debt of $12.9 billion at the end of Q2 2026, with a net debt to EBITDA ratio of 2.8x (2.3x excluding the MLX acquisition), and remains on track to achieve its target of below 2x net debt to EBITDA by 2027.
Business Finance, Finance, Financing & Debt
Project
Teva has outlined a pipeline launch sequence targeting one new asset per year over the next five years, including Olanzapine LAI in 2026, Ecopipam in 2027, and DARI and additional assets through 2028 to 2030, with combined pipeline peak sales potential of over $10 billion.
Earnings
reported that its biosimilar portfolio has grown to 15 products in market with 14 more in the pipeline, with 2 out of 5 US biosimilar products ranked number one, and the company on track to exceed its $800 million biosimilar revenue target by 2027.
Pharmaceuticals
Project
Teva has announced that its DARI dual-action rescue inhaler study for asthma is fully enrolled with over 2,700 patients, with the final event forecast by end of 2026 and data presentation expected in the first half of 2027.
Pharmaceuticals, Clinical Operations
Earnings
Corporate Strategy, Finance, Financial Operations
Teva News & Media
U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for ...
Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation NDA acceptance is supported by positive Phase 3 data, which were published in JAMA Neurology, and Phase 2b data If approved, ecopipam would be the first new treatment option indicated for pediatric patients with Tourette syndrome in more than 10 years and the first novel mechanism of action in more than 50 years 1 PARSIPPANY, N.J. and TEL AVIV, Israel, Aug.U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for ecopipam, with a targeted action (PDUFA) date late in the first quarter of 2027. Ecopipam is a first-in-class investigational therapy for the treatment of pediatric patients with Tourette syndrome. This milestone advaMoody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth StrategyWhy Teva Pharmaceutical Stock Surged This Week
Teva reported its Q2 results this week, but the stock's big gains mostly stemmed from another catalyst.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Teva
Sign Up For FreeTo access detailed company insights
Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical leader focused on improving health outcomes for patients worldwide. Enabled by a world-class generics business, Teva develops, manufactures, and delivers a broad portfolio of medicines, including complex generics, biosimilars, innovative therapies, and pharmacy brands. The company is... Read More
